Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?

Background: In progressive multiple sclerosis (MS), glial activation is thought to be a relevant mechanism of disability progression. Therefore, in vivo assessment of the glial cell activity is, in the emerging treatment era of primary progressive MS (PPMS), more important than ever. Objectives: To...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Neurol
Main Authors: Abdelhak, Ahmed, Hottenrott, Tilman, Morenas-Rodríguez, Estrella, Suárez-Calvet, Marc, Zettl, Uwe K., Haass, Christian, Meuth, Sven G., Rauer, Sebastian, Otto, Markus, Tumani, Hayrettin, Huss, André
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2019
Assuntos:
Neurology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6443875/
https://ncbi.nlm.nih.gov/pubmed/30972011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.00280
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares